EUVIMEDEUVIMED entdecken
Open Access

A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus

Zhenzhen Wang iD, Zhenhua Li iD, Weiwei Shi iD, Dashuai Zhu iD, Shiqi Hu iD, Phuong-Uyen C Dinh iD, Ke Cheng iD

Science Advances · 2023

DOI: 10.1126/sciadv.abo4100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2023. Verfasst von Zhenzhen Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, NC 27607, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Influenza A Virus, H1N1 Subtype, COVID-19. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The circulating flu viruses merging with the ongoing COVID-19 pandemic raises a more severe threat that promotes the infectivity of SARS-CoV-2 associated with higher mortality rates. Here, we conjugated recombinant receptor binding domain (RBD) of SARS-CoV-2 spike protein onto inactivated influenza A virus (Flu) to develop a SARS-CoV-2 virus-like particle (VLP) vaccine with two-hit protection. This double-hit vaccine (Flu-RBD) not only induced protective immunities against SARS-CoV-2 but also remained functional as a flu vaccine. The Flu core improved the retention and distribution of Flu-RBD vaccine in the draining lymph nodes, with enhanced immunogenicity. In a hamster model of live SARS-CoV-2 infection, two doses of Flu-RBD efficiently protected animals against viral infection. Furthermore, Flu-RBD VLP elicited a strong neutralization activity against both SARS-CoV-2 Delta pseudovirus and wild-type influenza A H1N1 inactivated virus in mice. Overall, the Flu-RBD VLP vaccine is a promising candidate for combating COVID-19, influenza A, and coinfection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanInfluenza A Virus, H1N1 SubtypeCOVID-19Influenza A virusCricetinaeAnimalsHumansMiceSARS-CoV-2PandemicsCOVID-19 VaccinesSpike Glycoprotein, Coronavirus

Substanzen

Influenza VaccinesCOVID-19 Vaccinesspike protein, SARS-CoV-2Spike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, NC 27607, USA.
  • Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, and North Carolina State University, Raleigh, NC 27606, USA.
  • Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

ORCID-Profile: Zhenzhen Wang, Zhenhua Li, Weiwei Shi, Dashuai Zhu, Shiqi Hu, Phuong-Uyen C Dinh, Ke Cheng

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Wang, Z., Li, Z., Shi, W., Zhu, D., Hu, S., Dinh, P. C., & Cheng, K. (2023). A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus. Science Advances. https://doi.org/10.1126/sciadv.abo4100

Vancouver

Wang Z, Li Z, Shi W, Zhu D, Hu S, Dinh PC, et al. A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus. Science Advances. 2023. doi:10.1126/sciadv.abo4100

BibTeX
@article{Wang2023,
  author = {Wang, Zhenzhen and Li, Zhenhua and Shi, Weiwei and Zhu, Dashuai and Hu, Shiqi and Dinh, Phuong-Uyen C and Cheng, Ke},
  title = {A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus},
  journal = {Science Advances},
  year = {2023},
  doi = {10.1126/sciadv.abo4100}
}
Kostenlos starten →